GSK wins FDA approval for Jemperli. GSK stock holds at EUR 22.25

Published on 10/21/2026 at 10:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jemperli wins US rectal cancer approval October 20, 2026. GSK stock costs EUR 22.25 on October 21, 2026, 0.14 percent above Xetra close EUR 22.22.

Approval and analyst targets

Jemperli received US approval for locally advanced rectal cancer on October 20, 2026, with a 68.00 percent response rate.
Jefferies reiterated a Buy rating and a GBp 2,500 target for GSK on October 20, 2026.
GSK stock trades at EUR 22.25 at 10:09 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.14 percent above the Xetra close of October 20, 2026.

GSK, GB00BN7SWP63, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) received US approval for Jemperli in locally advanced rectal cancer on October 20, 2026, while its stock stood at EUR 22.25 at Lang & Schwarz on October 21, 2026. The approval covers adults with stage II and III MSI-H or dMMR tumors, and the AZUR-1 study produced a 68.00 percent complete-response rate among 144 evaluable patients, according to Finanznachrichten.

Jemperli adds an oncology milestone

The FDA decision gives GSK a new treatment option for a biomarker-defined rectal-cancer group. The company said the treatment could help eligible patients avoid chemotherapy, radiation and surgery, while the study reported no disease recurrences among responders after a median follow-up of more than two years, according to Finanznachrichten.

Three dated signals for GSK

On September 18, 2026, GSK disclosed purchases of 1,500 ordinary shares at GBP 18.8110 by its chair, according to the SEC. On October 9, 2026, Wolfe Research began coverage with an Outperform rating and a USD 70.00 target, as reported by MarketBeat. The current event came on October 20, 2026, with the Jemperli approval and its 68.00 percent response figure.

What date comes next?

GSK is expected to publish third-quarter 2026 results before the market opens on October 28, 2026. The preview calls for USD 1.33 in earnings per share and USD 11.74 billion in revenue, according to MarketBeat. That report will test whether the oncology approval can complement the company's established vaccine, HIV and respiratory franchises.

Analyst target stays above the quote

Jefferies reiterated a Buy rating and a GBp 2,500 price target for GSK on October 20, 2026, according to MarketBeat. The target is a London-listed ordinary-share reference in pence, not a euro price and not the Lang & Schwarz quotation. GSK's primary listing is on the London Stock Exchange, where its ordinary shares carry the same ISIN confirmed in a trading admission notice from the Financial Times.

Stock holds near the Xetra close

GSK stock was trading at EUR 22.25 at Lang & Schwarz on October 21, 2026 at 10:09 a.m. CEST, plus 0.14 percent versus the Xetra close of October 20, 2026 at EUR 22.22. The modest spread keeps the approval story ahead of the October 28 results date as the next measurable test for the shares.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.